A double-blind study of azaribine in the treatment of psoriasis.
D000293:Adolescent; D000328:Adult; D001219:Aspartate Aminotransferases / Q000097:blood; D001706:Biopsy; D001792:Blood Platelets / Q000187:drug effects; D001806:Blood Urea Nitrogen; D002490:Central Nervous System / Q000187:drug effects; D002986:Clinical Trials as Topic; D004064:Digestive System / Q000187:drug effects; D005260:Female; D006454:Hemoglobins; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012156:Reticulocytes / Q000187:drug effects; D013997:Time Factors; D014227:Triazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D006454:Hemoglobins; D010919:Placebos; D014227:Triazines; D001219:Aspartate Aminotransferases